Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
Read Article
News
2024
2023
Archive
Search news articles
November 28, 2022
Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data From the Global Phase 3 Pivotal Restore Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in the Lancet
November 28, 2022
IDEAYA Biosciences Appoints Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline
November 28, 2022
Escient Pharmaceuticals Announces $120 Million Series C Financing
November 22, 2022
5AM Ventures Assists in Launching New Term Sheet Template for Early-Stage Life Science Startups Emerging from Academic Research Labs
November 22, 2022
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
November 22, 2022
scPharmaceuticals Announces Pricing of $50 Million Public Offering
November 21, 2022
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock
November 17, 2022
Escient Pharmaceuticals Initiates Phase 2 PACIFIC Study Evaluating EP547, An Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus
November 17, 2022
Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires
November 15, 2022
Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an ‘off-the shelf’ Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer
« Previous Page
1
2
3
4
5
…
103